chevron_leftBack
As of 24 April 2025, DiaSorin S.p.A. has a market cap of $6.01B USD, ranking #2485 globally and #34 in Italy. It ranks #211 in the Healthcare sector, and #23 in the Diagnostics & Research industry.
Key Stats
Market Cap
$6.01BUSD
5.31B EUR
Enterprise Value
$6.73BUSD
5.94B EUR
Revenue (TTM)
$1.34BUSD
1.19B EUR
EBITDA (TTM)
$413.59MUSD
364.96M EUR
Net Income (TTM)
$213.17MUSD
188.11M EUR
EBITDA Margin
31%
Profit Margin
16%
PE Ratio
29.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Carlo Rosa
open_in_new
Employees
3,308
Founded
1968
Website
int.diasorin.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.6% | -0.2% | 3.1% | -7.3% | -5.4% | 3.1% |
Upcoming Earnings
Earnings Date
Tue, May 6
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
DIA
Diasorin SpA
ISIN: IT0003492391
Shares Out.:
Shares Outstanding:
53.316M1
Shares Float:
21.044M2
|
98.48 EUR | |
|
0GZX
Diasorin SpA
ISIN: IT0003492391
|
97.82 EUR | |
|
DSRLF
Diasorin SpA
ISIN: IT0003492391
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
109.01 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About DiaSorin S.p.A.
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic LIAISON chemiluminescence analyzers under LIAISON XL and LIAISON XS name; and Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. The company was founded in 1968 and is headquartered in Saluggia, Italy.
